Please find enclosed the Financial Results for the Quarter ended 30th June 2026.
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 06 Aug 2026, 01:58 PM IST · BSE ID: ea1538e5-e3bf-4944-a91e-0bcc810f393f
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported a financial loss this quarter, with revenues at Rs. 9,417.85 lakhs.
🤖 AI Summary
- Zim Laboratories Ltd. reported a consolidated net loss after tax of Rs. (401.70) lakhs for the quarter ended 30 June 2026.
- Consolidated revenue from operations for Q1 FY27 was Rs. 9,417.85 lakhs.
- Total consolidated expenses for the quarter reached Rs. 10,074.38 lakhs.
- Basic and Diluted Earnings Per Share (EPS) for the quarter stood at Rs. (0.75).
- The Board approved the unaudited standalone and consolidated financial results on 06 August 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from operations (Q1 FY27)
9,417.85 Rs. in lakhs
31.24%
Consolidated Net Profit / (loss) after tax (Q1 FY27)
(401.70) Rs. in lakhs
Not comparable — limited prior period data.
Consolidated Basic EPS (Q1 FY27)
(0.75) Rs.
Not comparable — limited prior period data.
Total Consolidated Expenses (Q1 FY27)
10,074.38 Rs. in lakhs
33.15%
🏢 How This Affects the Company
The decline in revenue from operations from Rs. 10,527.34 lakhs in Q4 FY26 to Rs. 9,417.85 lakhs in Q1 FY27 indicates a contraction in sales during the quarter.
The company recorded a consolidated net loss after tax of Rs. (401.70) lakhs, moving from a profit of Rs. 373.99 lakhs in the preceding quarter, directly affecting profitability and retained earnings.
Not directly stated in the financial results. The increase in employee benefits expense to Rs. 1,918.37 lakhs from Rs. 1,739.15 lakhs suggests a potential change in workforce-related costs.
The shift to a net loss and increased expenses relative to revenue could signal short-term financial pressure, requiring close monitoring of cost management and revenue generation strategies.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required from shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders are impacted by the reported net loss of Rs. (401.70) lakhs and the negative Basic and Diluted EPS of Rs. (0.75), which reflects on the company's profitability for the quarter.
🔍
Management Signal
The management's approval and disclosure of these results indicate adherence to regulatory requirements and transparency regarding the company's Q1 FY27 financial performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — monitor revenue and profitability trends.
Management commentary during next earnings call for operational insights.
Any future announcements regarding cost control measures or revenue growth strategies.
MEDIUM RISK
The company reported a net loss for the quarter and a decline in revenue from previous quarter.
💡 Investor Takeaway
Zim Laboratories Ltd. reported a consolidated net loss after tax of Rs. (401.70) lakhs for the quarter ended 30 June 2026, a decline from Rs. 373.99 lakhs profit in the prior quarter. Revenue from operations for the quarter stood at Rs. 9,417.85 lakhs, lower than the Rs. 10,527.34 lakhs in Q4 FY26.
⚖️ Strengths & Concerns
⚠️ Concerns
- Net Profit after tax shifted to a loss of Rs. (401.70) lakhs in Q1 FY27 from a profit of Rs. 373.99 lakhs in Q4 FY26.
- Revenue from operations decreased to Rs. 9,417.85 lakhs in Q1 FY27 from Rs. 10,527.34 lakhs in the preceding quarter.
📅 Company Track Record
Zim Laboratories previously scheduled its Q4 & FY26 earnings call on May 20, 2026, following its Q4 FY26 results filing on May 13, 2026. This indicates a consistent reporting schedule for quarterly financial performance.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Zim Laboratories Ltd.'s consolidated net profit/loss for the quarter ended 30 June 2026?
Zim Laboratories Ltd. reported a consolidated net loss after tax of Rs. (401.70) lakhs for the quarter ended 30 June 2026.
What was Zim Laboratories Ltd.'s consolidated revenue from operations in Q1 FY27?
Consolidated revenue from operations for Zim Laboratories Ltd. was Rs. 9,417.85 lakhs for the quarter ended 30 June 2026.
How did Zim Laboratories Ltd.'s total expenses compare in Q1 FY27?
Total consolidated expenses for Zim Laboratories Ltd. were Rs. 10,074.38 lakhs for the quarter ended 30 June 2026.
What were the basic and diluted earnings per share for Zim Laboratories Ltd. in Q1 FY27?
Basic and Diluted Earnings Per Share (EPS) for Zim Laboratories Ltd. were Rs. (0.75) for the quarter ended 30 June 2026.
Questions based on this BSE filing only. For information purposes.